IV bolus of 60 U/kg (maximum 4000 U) followed by an infusion of 12 U/kg/h (maximum 1000 U) initially, adjusted to maintain aPTT at 1.5 to 2.0 times control (approximately 50 to 70 s) for 48 h or until revascularization. Enoxaparin: I A 332 335 If age <75 y: 30-mg IV bolus, followed in 15 min by 1 mg/kg subcutaneously every 12 h (maximum 100 mg for the first 2 doses) If age 75 y: no bolus, 0.75 mg/kg subcutaneously every 12 h (maximum 75 mg for the first 2 doses) Regardless of age, if CrCl <30 mL/min: 1 mg/kg subcutaneously every 24 h Duration: For the index hospitalization, up to 8 d or until revascularization Fondaparinux: I B 304 Initial dose 2.5 mg IV, then 2.5 mg subcutaneously daily starting the following day, for the index hospitalization up to 8 d or until revascularization Contraindicated if CrCl <30 mL/min aPTT indicates activated partial thromboplastin time; COR, Class of Recommendation; CrCl, creatinine clearance; IV, intravenous; LOE, Level of Evidence; N/A, not available; and UFH, unfractionated heparin. data on early catheterization and PCI after fibrinolysis in the stent era. Class I 1. Immediate transfer to a PCI-capable hospital for coronary angiography is recommended for suitable patients with STEMI who develop cardiogenic shock or acute severe HF, irrespective of the time delay from MI onset.354 (Level of Evidence: B) Class IIa 1. Urgent transfer to a PCI-capable hospital for coro- nary angiography is reasonable for patients with STEMI who demonstrate evidence of failed reperfu- sion or reocclusion after fibrinolytic therapy.346,355 357 (Level of Evidence: B) 2. Transfer to a PCI-capable hospital for coronary an- giography is reasonable for patients with STEMI who have received fibrinolytic therapy even when hemodynamically stable and with clinical evidence of successful reperfusion. 